CHINARES PHARMA (03320) has announced that its non-wholly owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd., has issued the first tranche of corporate bonds (2026 bonds) in China to qualified investors. The total principal amount does not exceed RMB 1 billion, with a maturity of three years and an annual interest rate of 1.65%. The net proceeds from the issuance of the first tranche of 2026 corporate bonds will be used to repay interest-bearing debt and supplement working capital.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments